Unanticipated efficacy of SARS-CoV-2 vaccination in older adults.
Immun Ageing
; 18(1): 7, 2021 Feb 17.
Article
in English
| MEDLINE | ID: covidwho-1088602
ABSTRACT
The rapidity with which vaccines against COVID-19 have been developed and tested is unprecedented. As classically the case with randomized clinical trials, many studies excluded older adults. However, given the early realisation that senior citizens were most highly susceptible to COVID, older individuals have been included in licensing trials under these unusual conditions. The recently published results from the Comirnaty Vaccine (BNT162b) trial unexpectedly documented that vaccine efficacy was equally exceptionally high in older and younger adults. These extremely encouraging trial results with a neoantigen vaccine may suggest the beginning of a paradigm shift in our view of the impact of immunosenescence on vaccination against novel infectious diseases.
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Type of study:
Experimental Studies
/
Prognostic study
/
Randomized controlled trials
Topics:
Vaccines
Language:
English
Journal:
Immun Ageing
Year:
2021
Document Type:
Article
Affiliation country:
S12979-021-00219-y
Similar
MEDLINE
...
LILACS
LIS